Novel Combo Falters in Metastatic Triple-Negative Breast Cancer

MedPage Today) — The combination of olaparib (Lynparza) and ceralasertib, an ataxia telangiectasia and RAD3-related inhibitor, did not improve outcomes in previously treated metastatic triple-negative breast cancer versus the PARP inhibitor alone…
Read More